MEA Neisseriaceae Infections Market

MEA Neisseriaceae Infections Market Size (2024 to 2029)

The Neisseriaceae Infections market in the Middle East and Africa is estimated to grow at a sluggish rate during the forecast period.

Over the forecast period, the MEA Neisseriaceae infections market is anticipated to witness significant growth due to the increased adoption of national immunization programs across various countries, especially in the MEA region. Additionally, the increase in meningococcal epidemics gonorrhea cases is driving the market. Gonorrhea is one of the most common sexually transmitted infections, with around 87 million new infections reported each year globally. Furthermore, increasing R&D activities associated with meningococcal vaccines, STD prevention programs, growing awareness about diseases caused by Neisseriaceae, and rising healthcare expenditures provide significant growth opportunities for the MEA Neisseriaceae infections market.

The growing prevalence of Neisseriaceae infections and other infectious diseases is the most significant factor driving the market growth to a higher level. According to the U.S Centres for Disease Control and Prevention (CDC), more than 300,000 new cases of gonorrhea were reported, with an increase of over 4% from 2011. On-going research and development activities have helped various drugs and formulations to enter the market. Moreover, due to the increased incidence of homosexuality and bisexuality, the threat of gonorrhea has also increased by several folds, especially in the regions of east and center Africa. The prevalence was recorded higher in women of the African continent, with around 4.31 million people infected, while the number of infections in men was reported to be 3.21 million. In Africa, the prevalence of N. gonorrhoeae infection was over 2.3%, with an incidence of 49.7 per 1000 population in 2008. In addition, meningococcal epidemics have increased the demand for meningococcal vaccines, further increasing market growth.

However, several factors which will hamper the MEA Neisseriaceae infections market includes stringent government rules, poor healthcare infrastructure, high cost of treatment and R&D, and negligence of symptoms of these infections.

This research report on the Middle East and Africa Neisseriaceae Infections market has been segmented and sub-segmented into the following categories.

By Type of Bacteria

• N. Meningitidis     
• N. Gonorrhoeae  
• N. Sicca    
• N. Flava   
• N. Elongata            
• N. Cinerea              
• Others     

By Disease

• Gonorrhea              
• Septicemia              
• Meningitis               
• Sinusitis    
• Otitis          
• Pneumonia             
• CNS            
• Urinary     
• Respiratory Infections

By Antibacterial Drugs

• Aminoglycosides (Streptomycin)
• B-Lactum Antibiotics (Penicillin)
• Clavulanic Acid (Augmentin)
• Glycopeptides (Vancomycin)
• Polypeptides (Bacitracin)
• Rifamycins (Rifampicin)
• Chloramphenicol
• Tetracycline

By Country

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

South Africa is the most lucrative market due to increased awareness of Gesneriaceae gonorrhea infections, ease of product availability, and the increasing prevalence of STIs. Due to all these factors, this regional market accounted for the largest market revenue market share in 2022. 

In 2008, the WHO estimated the global incidence of N. gonorrhea at 106 million cases, representing a 21% increase from the 2005 estimate. In Africa, the highest incidence was seen in western parts of Africa. In a detailed study, infections during pregnancy in sub-Saharan Africa and the prevalence of sexually transmitted and reproductive tract infections were comparable to malaria. The prevalence of N. gonorrhea during pregnancy ranged from 1.54% in West and Central Africa to 4.94% in East and Southern Africa. One of the main factors responsible for raising the rates of gonorrhea, particularly in sub-Saharan Africa, is the increase in the prevalence of HIV infection.

Other MEA regions such as Saudi Arabia, UAE, Qatar, Turkey, and Egypt are estimated to represent steady growing countries, mainly attributed to a large population, better access to healthcare systems, and increased awareness of these infections.

KEY MARKET PLAYERS

Companies dominating the MEA Neisseriaceae Infections market leaders are Aphios Corporation, Basilea Pharmaceuticals Ltd., Pfizer, Inc., GSK plc, AstraZeneca plc, Adenium Biotech ApS, Dainippon Sumitomo Pharma Co., Ltd., Theravance, Inc., and Pfizer, Inc. amongst many others.